Mini Review

Standardization of Herbal Drugs: Challenges and Current Practices in Pharmacognosy

Sunny Kumar Patel

Department of Pharmacy,
ALBLA College of Pharmacy,
Gujrat, India

Correspondence:
Dr. Sunny Kumar Patel,
Department of Pharmacy,
ALBLA College of Pharmacy,
Gujrat, India
E-id: - patel.sunnykumar@gmail.com

How to cite this article: Patel SK. Standardization of Herbal Drugs: Challenges and Current Practices in Pharmacognosy. Innov Pharm Planet (IP-Planet) 2020;8(4):34-36.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 13-10-2020
Date of Revision: 31-10-2020
Date of Acceptance: 09-11-2020

Abstract

The standardization of herbal drugs is crucial for ensuring their safety, efficacy, and consistent quality in modern healthcare. Unlike synthetic pharmaceuticals, herbal drugs are derived from complex plant materials, making them highly susceptible to chemical variability, environmental influences, and risks of adulteration or contamination. These challenges are further exacerbated by the lack of universally accepted quality standards and regulatory harmonization, hindering their seamless integration into mainstream medicine.

This review explores the key obstacles in herbal drug standardization, including stability concerns, variations in raw material composition, and analytical complexities. Current practices in pharmacognosy emphasize techniques such as phytochemical profiling, chromatography-based analyses, DNA barcoding, and Good Agricultural and Collection Practices (GACP) to enhance quality control. Additionally, the development of pharmacopoeial monographs provides standardized guidelines for identification, purity assessment, and potency evaluation.

Advancements in metabolomics, chemometric modeling, and artificial intelligence-driven analytics are revolutionizing the quality assurance process, offering high-throughput and precise methodologies for detecting inconsistencies and ensuring reproducibility. These cutting-edge approaches facilitate fingerprinting, batch-to-batch consistency, and predictive modeling, significantly improving regulatory compliance.

The establishment of globally recognized, evidence-based standards is imperative to promote the safe and effective use of herbal drugs, fostering greater trust among healthcare providers, researchers, and patients. A collaborative effort involving scientific advancements, regulatory reforms, and industry compliance will be key to ensuring the long-term success of herbal medicine in modern therapeutics.

Keywords: Herbal drugs, Standardization, Phytochemical profiling, DNA barcoding, Good agricultural and collection practices (GACP)

Introduction

Herbal drugs have been integral to traditional medicine systems worldwide and are increasingly gaining recognition in modern healthcare. The global surge in the use of herbal medicines is driven by their perceived safety, efficacy, and cultural acceptance. However, the scientific validation and standardization of herbal drugs remain significant challenges in pharmacognosy. Unlike synthetic drugs, chemically well-defined, herbal drugs are com plex mixtures of bioactive compounds, making their standardization a multifaceted process.

This mini-review discusses the challenges in standardizing herbal drugs and explores current practices in pharmacognosy to ensure their safety, efficacy, and quality.[1]

Access this article online	
Website: https://innovationaljournals.com/index.php/ip	**e-ISSN:** 2348-7275

Challenges in Standardizing Herbal Drugs

1. Complexity of Herbal Preparations

Herbal drugs often contain a combination of primary and secondary metabolites, including alkaloids, flavonoids, glycosides, and tannins. These compounds vary depending on the plant species, part used, geographic location, cultivation practices, and processing methods. The heterogeneity in chemical composition complicates the identification of active constituents and their quantification.[2]

2. Lack of Defined Standards

Unlike synthetic pharmaceuticals, many herbal drugs lack universally accepted standards for purity, potency, and identity. Variability in plant materials and the absence of consistent regulatory frameworks lead to quality discrepancies among herbal products.[3]

3. Adulteration and Contamination

The adulteration of herbal drugs with synthetic chemicals, substandard materials, or fillers poses significant risks to

consumer safety. Contamination with heavy metals, pesticides, or microbial pathogens further complicates standardization efforts.[4]

4. Stability and Shelf-Life Issues

Herbal formulations are often susceptible to degradation due to environmental factors such as humidity, light, and temperature. Ensuring the stability and shelf-life of herbal products requires comprehensive testing and the development of suitable preservation techniques.[5]

5. Analytical Challenges

The complexity of herbal drugs makes their analysis challenging. Advanced analytical techniques, such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS), are often required to identify and quantify bioactive constituents. However, the high cost and technical expertise required for these methods limit their widespread application.[6]

Current Practices in Standardization

1. Phytochemical Profiling

Phytochemical profiling involves the identification and quantification of active and marker compounds in herbal drugs. Techniques such as HPLC, gas chromatography (GC), and nuclear magnetic resonance (NMR) spectroscopy are commonly used to create a chemical fingerprint of herbal products. These fingerprints serve as reference standards for quality control.[7]

1. DNA Barcoding

DNA barcoding is a molecular technique used to authenticate the botanical origin of herbal drugs. By analyzing specific DNA sequences, this method helps distinguish genuine plant materials from adulterants or substitutes, ensuring the authenticity of herbal drugs.[8]

2. Good Agricultural and Collection Practices (GACP)

GACP guidelines emphasize standardized cultivation, harvesting, and post-harvest processing of medicinal plants. These practices ensure the consistent quality of raw materials by minimizing variations caused by environmental and agricultural factors.[9]

3. Standardized Extracts

Standardized extracts are herbal preparations with consistent levels of one or more bioactive constituents. These extracts are prepared using validated extraction techniques and are often used in clinical studies to ensure the reproducibility of therapeutic effects.[10]

4. Pharmacopoeial Monographs

Many countries have developed pharmacopoeial monographs for herbal drugs, which provide detailed specifications for their identification, quality, and purity. Examples include the Indian Pharmacopoeia, the Chinese Pharmacopoeia, and the European Pharmacopoeia.

5. Toxicological and Clinical Evaluations

Comprehensive toxicological testing, including acute and chronic toxicity studies, is essential for establishing the safety of herbal drugs. Clinical trials validate their efficacy and safety in humans, ensuring they meet modern regulatory standards.[11]

Future Perspectives

Advancements in technology and regulatory harmonization hold promise for overcoming the challenges in herbal drug standardization. Emerging techniques such as metabolomics, proteomics, and artificial intelligence (AI)-driven analytics can provide deeper insights into the complex composition of herbal drugs. Moreover, global collaboration in developing standardized guidelines and regulatory frameworks will play a pivotal role in ensuring the quality and safety of herbal medicines.[12]

Conclusion

The standardization of herbal drugs is a critical component of ensuring their safety, efficacy, and global acceptance. While significant progress has been made, challenges such as chemical complexity, variability, and adulteration persist. Current practices in pharmacognosy, including phytochemical profiling, DNA barcoding, and standardized extracts, provide robust tools for addressing these challenges. Continued research, technological innovation, and regulatory harmonization are essential to advance the field and establish herbal drugs as reliable therapeutic options in modern medicine.

This review highlights the importance of rigorous standardization practices to bridge the gap between traditional knowledge and modern scientific validation in the field of pharmacognosy.

References

1. Srivastava, S., & Misra, A. (2018). Quality control of herbal drugs: Advancements and challenges. New Age Herbals: Resource, Quality and Pharmacognosy, 189-209.
2. Govindaraghavan, S., & Sucher, N. J. (2015). Quality assessment of medicinal herbs and their extracts: Criteria and prerequisites for consistent safety and efficacy of herbal medicines. Epilepsy & Behavior, 52, 363-371.
3. Li, F. S., & Weng, J. K. (2017). Demystifying traditional herbal medicine with modern approach. Nature plants, 3(8), 1-7.
4. Alam, G., & Mishra, A. K. (2017). Traditional and modern approaches for standardization of herbal drugs: a review. Acta Biomedica Scientia e-ISSN, 2348, 2168.
5. Alamgir, A. N. M., & Alamgir, A. N. M. (2017). Herbal drugs: their collection, preservation, and preparation; evaluation, quality control, and standardization of herbal drugs. Therapeutic Use of Medicinal Plants and Their Extracts: Volume 1: Pharmacognosy, 453-495.
6. Li, F. S., & Weng, J. K. (2017). Demystifying traditional herbal medicine with modern approach. Nature plants, 3(8), 1-7
7. Nafiu, M. O., Hamid, A. A., Muritala, H. F., & Adeyemi, S. B. (2017). Preparation, standardization, and quality control of medicinal plants in Africa. Medicinal spices and vegetables from Africa, 171-204.
8. de Boer, H. J., Ichim, M. C., & Newmaster, S. G. (2015). DNA barcoding and pharmacovigilance of herbal medicines. Drug

safety, 38, 611-620.
9. Rawat, A. K. S., & Tewari, S. K. (2015). Quality Assurance of Medicinal and Aromatic Plants-Good Agricultural and Collection Practices (GAP & GCP). Medicinal and Aromatic Plants of the World: Scientific, Production, Commercial and Utilization Aspects, 273-303.
10. Kumari, R., & Kotecha, M. (2016). A review on the standardization of herbal medicines. International journal of pharma sciences and research, 7(2), 97-106.
11. Mensah, M. L., Komlaga, G., Forkuo, A. D., Firempong, C., Anning, A. K., & Dickson, R. A. (2019). Toxicity and safety implications of herbal medicines used in Africa. Herbal medicine, 63(5), 1992-0849.
12. Tiwari, R., Latheef, S. K., Ahmed, I., Iqbal, H. M., Bule, M. H., Dhama, K., ... & Farag, M. R. (2018). Herbal immunomodulators-a remedial panacea for designing and developing effective drugs and medicines: current scenario and future prospects. Current drug metabolism, 19(3), 264-301.
13. Hollis, A. (2016). Sustainable financing of innovative therapies: a review of approaches. Pharmacoeconomics, 34(10), 971-980.
14. Maceira, D. (2013). Analysing the Access to Priority Health Services in the Adolescent Population in Six Provinces in Northern Argentina. Value in Health, 16(7), A673.
15. Bommer, C., Sagalova, V., Heesemann, E., Manne-Goehler, J., Atun, R., Bärnighausen, T., ... & Vollmer, S. (2018). Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes care, 41(5), 963-970.
16. Moreno, S. G., & Epstein, D. (2019). The price of innovation-the role of drug pricing in financing pharmaceutical innovation. A conceptual framework. Journal of market access & health policy, 7(1), 1583536.
17. Frois, C., & Grueger, J. (2017). Pricing of pharmaceuticals: current trends and outlook and the role of comparative effectiveness research. Decision Making in a World of Comparative Effectiveness Research: A Practical Guide, 75-93.
18. Abbott, F. M. (2016). Public-Private Partnerships As Models for New Drug Development: The Future As Now. The Cambridge Handbook of Public-Private Partnerships, Intellectual Property Governance, and Sustainable Development, 29-45.
19. Addivinola Jr, F. J. (2018). The Effects of the Biologics Price Competition and Innovation Act of 2009 on Biopharmaceutical Research and Development (Doctoral dissertation, Northeastern University).
20. Nass, S. J., Madhavan, G., & Augustine, N. R. (Eds.). (2018). Making medicines affordable: a national imperative.
21. Mayo, T. C. (2017). Innovative Pricing Models Potentially Drive Payer Coverage: A Market Access Case Study for RNAi Therapeutics (Doctoral dissertation).